Table 6 Cost-effectiveness ranking per patient (patient perspective)
Strategy | Cost (US$) | Incr cost (US$) | Eff(QALY) | Incr Eff(QALY) | Incr C/E (US$/QALY) | NMB (US$) | INMB (US$) | C/E (US$/QALY) |
|---|---|---|---|---|---|---|---|---|
Sorafenib | 16,109.80 | 0.00 | 1.30 | 0.00 | 0.00 | 31,470.20 | 0.00 | 12,392.15 |
Lenvatinib | 23,654.81 | 7,545.01 | 1.34 | 0.04 | 188,625.25 | 25,389.19 | − 6,081.01 | 17,652.84 |
Sintilimab-Bevacizumab | 39,406.40 | 23,296.60 | 1.61 | 0.31 | 75,150.32 | 19,519.60 | − 11,950.60 | 24,476.02 |
Atezolizumab-Bevacizumab | 141,836.73 | 125,726.93 | 2.17 | 0.87 | 144,513.71 |  − 62,414.73 | − 93,884.93 | 65,362.55 |